16th Annual Orange County Symposium for Cardiovascular Disease Prevention: Strategies for Success

The Orange County Symposium for Cardiovascular Disease Prevention is designed to fill knowledge gaps in the fast-evolving field of preventive cardiology. Primary care providers, cardiologists, endocrinologists, lifestyle interventionists, and other specialists will be updated this year on: 1) How practices from hunter gatherer populations inform us about preventing heart disease 2) Role of the mammogram and breast arterial calcification in informing women of their cardiovascular risk 3) Importance of inflammation as a major cause of cardiovascular disease 4) Role of epigenetics in cardiovascular disease prevention 5) How polygenic risk scoring can inform precision cardiovascular care 6) Importance of social determinants of health in preventive cardiology 7) Nutraceuticals in cardiovascular disease prevention 8) Non-Alcoholic Fatty Liver Disease and CVD – What’s the Connection? 9) The new Cardio-Kidney-Metabolic Syndrome and its importance in cardiovascular disease 10) Lipoprotein(a) as the new frontier in cardiovascular prevention 11) GLP1-RA therapy in obesity management and the prevention of cardiovascular disease 12) Triglyceride Rich Lipoproteins and Why They are Important

In-person: Sue Gross Auditorium - 856 Health Sciences Rd., Irvine, CA

1. Discuss how practices from hunter gatherer populations inform us about atherosclerosis
2. Discuss the role of the mammogram and breast arterial calcification in informing women of their cardiovascular risk
3. Discussion evaluation of the vulnerable plaque and patient and implications for cardiovascular disease prevention
4. Discuss the importance of inflammation as a major cause of cardiovascular disease
5. Discuss the emerging epidemic of atrial fibrillation and strategies for its prevention and management
6. Discuss the role of epigenetics in cardiovascular disease prevention
7. Discuss how polygenic risk scoring can inform precision cardiovascular care
8. Discuss the role of maternal nutrition in cardiovascular disease prevention
9. Discuss the role of non-Alcoholic Fatty Liver Disease and CVD
10. Discuss the new Cardio-Kidney-Metabolic Syndrome and its importance in cardiovascular disease
11. Discuss the role of lipoprotein(a) in cardiovascular prevention
12. Discuss the role of GLP1-RA therapy in obesity management and the prevention of cardiovascular disease
13. Discuss the role of triglyceride rich lipoproteins and why they are important
14. Discuss the role of stress and how to manage it for the prevention of cardiovascular disease

ADA Statement: In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request.  For any special requests, please contact the activity administrator before the meeting date.

For more information, please contact Lucy Gonzales at [email protected].

The University of California, Irvine School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Robert Greenfield, MD, PhD
Assistant Professor of Cardiology, Department of Medicine
UCI School of Medicine

Co-Director, Faculty

Nothing to disclose

Shaista Malik, MD, PhD, MPH, FACC
Associate Vice Chancellor for Integrative Health; Professor & Program Director, Cardiovascular Disease Fellowship
UCI School of Medicine

Co-Director, Faculty

Ownership-FluxWear

Paul Rosenblit, MD, PhD, FACE, FNLA
Clinical Professor of Endocrinology, Diabetes, and Metabolism, Department of Medicine
Diabetes / Lipid Management & Research Center

Co-Director, Faculty

Independent Contractor (included contracted research)-Esperian|Honoraria-Esperian|Speakers Bureau-Esperian|Grant or research support-Novartis Corporation Pharmaceuticals|Grant or research support-Novo Nordisk (Any division)|Grant or research support-Ionis Pharmaceuticals

Nathan D. Wong, PhD, MPH
Professor and Director, Heart Disease Prevention Program
UCI School of Medicine

Course Director, Faculty

Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division)

Lori B. Daniels, MD, MAS; FACC, FAHA
Professor of Medicine
UC San Diego

Faculty

Consulting Fee-Roche (Any division)|Honoraria-Abbott (Any division) (Relationship has ended)|Consulting Fee-Quidel Ortho|Stocks or stock options, excluding diversified mutual funds-Vektor Medical|Grant or research support-Roche (Any division)

David M. Donaldson, MD
Associate Professor of Medicine
UCI School of Medicine

Faculty

Consulting Fee-Edwards Lifesciences Corporation

P. Barton Duell, MD, FAHA, MNLA
Professor of Medicine
Oregon Health & Science University

Faculty

Advisor-Esperion|Consulting Fee-Ionis Pharmaceuticals|Consulting Fee-Novo Nordisk (Any division) (Relationship has ended)|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Kaneka (Relationship has ended)|Advisor-Mirum -Travere - Retrophin|Consulting Fee-New Amsterdam

Richard J Glassock, MD
Emeitus Professor
American Society of Nephrology

Faculty

Consulting Fee-Travere|Consulting Fee-BioCryst|Advisor-Novartis|Advisor-Otsuka|Consulting Fee-Alexion|Advisor-Vera|Consulting Fee-Kezar|Advisor-Genentech (Any division)

Yehuda Handelsman, MD
Medical Director & Principal Investigator
Metabolic Institute of America

Faculty

Grant or research support-Applied Therapeutic (Relationship has ended)|Grant or research support-Corcept|Grant or research support-Ionis|Grant or research support-Lilly (Any division) (Relationship has ended)|Grant or research support-Merck (Any division)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Consulting Fee-89Bio (Relationship has ended)|Consulting Fee-, Applied Therapeutic (Relationship has ended)|Consulting Fee-Amgen, Inc. (Relationship has ended)|Advisor-AstraZeneca (Any division) (Relationship has ended)|Advisor-Bayer (Any division) (Relationship has ended)|Advisor-Boehringer Ingelheim Pharmaceuticals, Inc. (Relationship has ended)|Advisor-Corcept|Advisor-Regeneron Pharmaceuticals, Inc.|Advisor-Endogenex (Relationship has ended)|Honoraria-Novo Nordisk (Any division)

Karen Lindsay, RDN, RDN
UC Irvine

Faculty

Nothing to disclose

Jagat Narula, MD, PhD, MACC
UTHealth Houston

Faculty

Nothing to disclose

Jamal S. Rana, MD, PhD

Faculty

Nothing to disclose

Gregory Thomas, MD, MPH
Medical Director Emeritus, MHVI CV Program Deveopment
MemorialCare

Faculty

Nothing to disclose

John W. Zamarra, MD
Physician, Cardiology & Family Medicine
Transformation Health & Wellness

Faculty

Nothing to disclose

Saturday, November 2, 2024